Is REPL research on Rallies investment advice?

No. Rallies provides research, data, and educational context for REPL. It does not provide personalized investment advice.

REPL (Replimune Group, Inc.) Stock Analysis - Financials

Replimune Group, Inc. (REPL) is a publicly traded Healthcare sector company. As of September 3, 2026, REPL trades at $15.93 with a market cap of $1.48B and a P/E ratio of -4.76. REPL moved +0.00% today. Year to date, REPL is +64.40%; over the trailing twelve months it is +170.85%. Its 52-week range spans $1.50 to $16.33. Analyst consensus is strong buy with an average price target of $19.17. Rallies surfaces REPL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are REPL's key financials?

REPL financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. REPL recently traded at $15.93. Market cap is $1.48B. P/E ratio is -4.76. Revenue is $0.

REPL Key Metrics

Key financial metrics for REPL
Metric	Value
Price	$15.93
Market Cap	$1.48B
P/E Ratio	-4.76
EPS	$-3.38
Dividend Yield	0.00%
52-Week High	$16.33
52-Week Low	$1.50
Volume	33.48K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-313.94M
Gross Margin	0.00%

REPL Analyst Consensus

7 analysts cover REPL: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $19.17.

Common questions about REPL

What are REPL's key financials?: REPL financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. REPL recently traded at $15.93. Market cap is $1.48B. P/E ratio is -4.76. Revenue is $0.
Is REPL research on Rallies investment advice?: No. Rallies provides research, data, and educational context for REPL. It does not provide personalized investment advice.